Home › Funds › MPM BioImpact LLC › MLTX
MPM BioImpact LLC position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
MPM BioImpact LLC reported holding 1,606,967 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$31.3M, representing 1.91% of its reported portfolio and ranking #19 among its reported holdings. MPM BioImpact LLC has disclosed MLTX holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's MLTX position evolved
MPM BioImpact LLC first disclosed a stake in MLTX in Q3 2023 at 294,190 shares (US$16.8M). The position peaked in Q1 2026 at 1,811,082 shares, worth US$33.8M. Across 10 filings, MPM BioImpact LLC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,606,967 shares valued at US$31.3M — a reduction of -204,115 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 294.19K | $16.77M | New |
| Q4 2023 | 294.58K | $17.79M | Hold |
| Q1 2024 | 296.05K | $14.87M | Add |
| Q2 2024 | 343.24K | $15.09M | Add |
| Q3 2024 | 349.06K | $17.60M | Add |
| Q4 2024 | 315.23K | $17.07M | Reduce |
| Q1 2025 | 316.05K | $12.35M | Hold |
| Q2 2025 | 313.57K | $14.80M | Reduce |
| Q1 2026 | 1.81M | $33.76M | New |
| Q2 2026 | 1.61M | $31.29M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 29 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held MLTX?
MPM BioImpact LLC has disclosed MLTX holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
What is MPM BioImpact LLC's current position in MLTX?
As of Q2 2026, MPM BioImpact LLC holds 1.61M shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $31.29M, representing 1.91% of its reported portfolio and ranking #19.
Has MPM BioImpact LLC been buying or selling MLTX?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in MLTX. The position peaked in Q1 2026 at 1.81M shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.